Coherus BioSciences shared its Q3 2026 earnings, showing $14 million in sales and a 3% growth from last quarter.

Nov 9, 2026, 6:21 PM ETResultsRead the original at Benzinga

Neutral

Coherus reported sales growth but missed its stated target. Planned job cuts and a narrower cancer focus may help, but the savings and future sales goals are not yet results.

CHRS · Coherus BioSciences

AI read · Neutral

The AI's read

The planned staffing cuts could reduce Coherus's cash use, and the company is narrowing its cancer work to an area supported by clinical data. But the sales target was missed, and the cost savings, future LOQTORZI sales goal, and overseas partner talks are not yet results. The facts point in different directions.

Get alerts for CHRS

Follow Coherus BioSciences (CHRS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CHRS

Free on the App Store and Google Play, or on the web.